Home The Word Brain	My Amedeo FAQ Privacy About	Flying Publisher
	COVID Reference, 5th edition, 486 pages Free download

Gastric Cancer

Free Subscription Articles published in J Surg Oncol Retrieve available abstracts of 99 articles: HTML format

Single Articles

September 2020
1. CHOI AH, Ji L, Babcock B, Ramos V, et al
   Peritoneal carcinomatosis in gastric cancer: Are Hispanics at higher risk?
   J Surg Oncol. 2020 Sep 9. doi: 10.1002/jso.26210.
   PubMed     Abstract available
   
   
   
2. LAMBERTI G, Manuzzi L, Maggio I, Campana D, et al
   Should we lose hope in adjuvant therapy for neuroendocrine tumors?-In response to: Adjuvant therapy following resection of gastroenteropancreatic neuroendocrine tumors provides no recurrence or survival benefit.
   J Surg Oncol. 2020;122:570-571.
   PubMed    
   
   
   
3. BARRETT JR, Abbott DE
   Adjuvant therapy following resection of gastroenteropancreatic neuroendocrine tumors-There is hope, but more data are needed.
   J Surg Oncol. 2020;122:572.
   PubMed    
   
   
   
4. SUGITA S, Kuwata T, Tokunaga M, Kaito A, et al
   Clinical significance of lymphatic invasion in the esophageal region in patients with adenocarcinoma of the esophagogastric junction.
   J Surg Oncol. 2020;122:433-441.
   PubMed     Abstract available
   
   
   August 2020
5. BLUMENTHALER AN, Ikoma N, Blum M, Das P, et al
   Relationship between initial management strategy and survival in patients with gastric outlet obstruction due to gastric cancer.
   J Surg Oncol. 2020 Aug 18. doi: 10.1002/jso.26177.
   PubMed     Abstract available
   
   
   
6. ASKARI A, Munster AB, Jambulingam P, Riaz A, et al
   Critical number of lymph node involvement in esophageal and gastric cancer and its impact on long-term survival-A single-center 8-year study.
   J Surg Oncol. 2020 Aug 16. doi: 10.1002/jso.26145.
   PubMed     Abstract available
   
   
   July 2020
7. JU MR, Wang SC, Zeh HJ, Porembka MR, et al
   Minimally invasive gastrectomy for cancer and anastomotic options.
   J Surg Oncol. 2020;122:49-60.
   PubMed     Abstract available
   
   
   June 2020
8. BENCIVENGA M, Treppiedi E, Dal Cero M, Torroni L, et al
   The amount of signet ring cells is significantly associated with tumour stage and survival in gastric poorly cohesive tumours.
   J Surg Oncol. 2020;121:1084-1089.
   PubMed     Abstract available
   
   
   
9. BARRETT JR, Rendell V, Pokrzywa C, Lopez-Aguiar AG, et al
   Adjuvant therapy following resection of gastroenteropancreatic neuroendocrine tumors provides no recurrence or survival benefit.
   J Surg Oncol. 2020;121:1067-1073.
   PubMed     Abstract available
   
   
   May 2020
10. STARK AP, Estrella JS, Chiang YJ, Das P, et al
    Impact of tumor regression grade on recurrence after preoperative chemoradiation and gastrectomy for gastric cancer.
    J Surg Oncol. 2020 May 27. doi: 10.1002/jso.25984.
    PubMed     Abstract available
    
    
    
11. HUR H, Roh CK, Son SY, Han SU, et al
    How could we make clinical evidence for early recovery after surgery (ERAS) in minimally invasive surgery for gastric cancer?
    J Surg Oncol. 2020 May 17. doi: 10.1002/jso.25955.
    PubMed    
    
    
    
12. HU Q, Yang X
    Comment on "Clinical pathway for enhanced recovery after surgery for gastric cancer: A prospective single-center phase II clinical trial for safety and efficacy".
    J Surg Oncol. 2020 May 17. doi: 10.1002/jso.25954.
    PubMed    
    
    
    
13. CHEN E, Senders ZJ, Hardacre J, Kim J, et al
    Perioperative outcomes and survival of octogenarians undergoing curative resection for esophagogastric adenocarcinoma.
    J Surg Oncol. 2020;121:1015-1021.
    PubMed     Abstract available
    
    
    April 2020
14. AGNES A, Biondi A, Laurino A, Strippoli A, et al
    A detailed analysis of the recurrence timing and pattern after curative surgery in patients undergoing neoadjuvant therapy or upfront surgery for gastric cancer.
    J Surg Oncol. 2020 Apr 29. doi: 10.1002/jso.25959.
    PubMed     Abstract available
    
    
    
15. DIAS AR, Pereira MA, Oliveira RJ, Ramos MFKP, et al
    Multivisceral resection vs standard gastrectomy for gastric adenocarcinoma.
    J Surg Oncol. 2020;121:840-847.
    PubMed     Abstract available
    
    
    March 2020
16. CROWN A, Rocha FG, Raghu P, Lin B, et al
    Impact of initial imaging with gallium-68 dotatate PET/CT on diagnosis and management of patients with neuroendocrine tumors.
    J Surg Oncol. 2020;121:480-485.
    PubMed     Abstract available
    
    
    
17. FARROW NE, Freischlag KW, Adam MA, Blazer DG, et al
    Impact of minimally invasive gastrectomy on use of and time to adjuvant chemotherapy for gastric adenocarcinoma.
    J Surg Oncol. 2020;121:486-493.
    PubMed     Abstract available
    
    
    January 2020
18. DINIZ TP, da Costa WL Jr, Fonseca de Jesus VH, Ribeiro HSC, et al
    Does hipec improve outcomes in gastric cancer patients treated with perioperative chemotherapy and radical surgery? A propensity-score matched analysis.
    J Surg Oncol. 2020 Jan 16. doi: 10.1002/jso.25823.
    PubMed     Abstract available
    
    
    
19. CHARRUF AZ, Ramos MFKP, Pereira MA, Dias AR, et al
    Impact of neoadjuvant chemotherapy on surgical and pathological results of gastric cancer patients: A case-control study.
    J Surg Oncol. 2020 Jan 14. doi: 10.1002/jso.25839.
    PubMed     Abstract available
    
    
    
20. ROH CK, Son SY, Lee SY, Hur H, et al
    Clinical pathway for enhanced recovery after surgery for gastric cancer: A prospective single-center phase II clinical trial for safety and efficacy.
    J Surg Oncol. 2020 Jan 12. doi: 10.1002/jso.25837.
    PubMed     Abstract available
    
    
    
21. TSAO MW, Delozier OM, Stiles ZE, Magnotti LJ, et al
    The impact of race and socioeconomic status on the presentation, management and outcomes for gastric cancer patients: Analysis from a metropolitan area in the southeast United States.
    J Surg Oncol. 2020 Jan 4. doi: 10.1002/jso.25827.
    PubMed     Abstract available
    
    
    December 2019
22. RAMOS MFKP, Pereira MA, Amorim LC, de Mello ES, et al
    Gastric cancer molecular classification and adjuvant therapy: Is there a different benefit according to the subtype?
    J Surg Oncol. 2019 Dec 3. doi: 10.1002/jso.25792.
    PubMed     Abstract available
    
    
    
23. ALLEN CJ, Newhook TE, Vreeland TJ, Das P, et al
    Yield of peritoneal cytology in staging patients with gastric and gastroesophageal cancer.
    J Surg Oncol. 2019;120:1350-1357.
    PubMed     Abstract available
    
    
    November 2019
24. PEREIRA MA, Ramos MFKP, Dias AR, Cardili L, et al
    Lymph node regression after neoadjuvant chemotherapy: A predictor of survival in gastric cancer.
    J Surg Oncol. 2019 Nov 26. doi: 10.1002/jso.25785.
    PubMed     Abstract available
    
    
    
25. COIMBRA FJF, de Jesus VHF, Franco CP, Calsavara VF, et al
    Predicting overall and major postoperative morbidity in gastric cancer patients.
    J Surg Oncol. 2019 Nov 6. doi: 10.1002/jso.25743.
    PubMed     Abstract available
    
    
    
26. WOHNRATH DR, Araujo RLC
    Positive node-ratio in curative-intent treatment for gastric cancer is a strong independent prognostic factor for 5-year overall survival.
    J Surg Oncol. 2019 Nov 5. doi: 10.1002/jso.25755.
    PubMed     Abstract available
    
    
    
27. VAN BEEK DJ, Nell S, Pieterman CRC, de Herder WW, et al
    Prognostic factors and survival in MEN1 patients with gastrinomas: Results from the DutchMEN study group (DMSG).
    J Surg Oncol. 2019;120:966-975.
    PubMed     Abstract available
    
    
    
28. DEPALO DK, Lee RM, Lopez-Aguiar AG, Gamboa AC, et al
    Interaction of race and pathology for neuroendocrine tumors: Epidemiology, natural history, or racial disparity?
    J Surg Oncol. 2019;120:919-925.
    PubMed     Abstract available
    
    
    October 2019
29. SIERZEGA M, Chrzan R
    Sarcopenia associated with gastric cancer.
    J Surg Oncol. 2019 Oct 23. doi: 10.1002/jso.25744.
    PubMed    
    
    
    
30. OHMORI Y, Nomura T, Fukushima N, Takahashi F, et al
    Recurrence risk evaluation in T1N1M0/T2N0M0/T3N0M0 gastric cancer with TP53 codon 72 polymorphisms.
    J Surg Oncol. 2019 Oct 2. doi: 10.1002/jso.25718.
    PubMed     Abstract available
    
    
    September 2019
31. RAWICZ-PRUSZYNSKI K, Mielko J, Pudlo K, Lisiecki R, et al
    Yield of staging laparoscopy in gastric cancer is influenced by Lauren histologic subtype.
    J Surg Oncol. 2019 Sep 23. doi: 10.1002/jso.25711.
    PubMed     Abstract available
    
    
    
32. SONODA K, Samdani RT, Ikoma N, Kaya DM, et al
    Gastric cancer in the remnant stomach after pancreaticoduodenectomy: A case series.
    J Surg Oncol. 2019 Sep 9. doi: 10.1002/jso.25695.
    PubMed     Abstract available
    
    
    
33. DU J, Xue H, Zhao L, Hua J, et al
    Intracorporeal circular-stapled anastomosis after totally laparoscopic gastrectomy: A novel, simplest u-shaped parallel purse-string suture technique.
    J Surg Oncol. 2019;120:501-507.
    PubMed     Abstract available
    
    
    
34. SIERZEGA M, Chrzan R, Wiktorowicz M, Kolodziejczyk P, et al
    Prognostic and predictive implications of sarcopenia in Western patients undergoing gastric resections for carcinoma of the stomach.
    J Surg Oncol. 2019;120:473-482.
    PubMed     Abstract available
    
    
    August 2019
35. ULANJA MB, Beutler BD, Rishi M, Konam KG, et al
    Influence of race and geographic setting on the management of gastric adenocarcinoma.
    J Surg Oncol. 2019;120:270-279.
    PubMed     Abstract available
    
    
    
36. LI S, Chung DC, Mullen JT
    Screening high-risk populations for esophageal and gastric cancer.
    J Surg Oncol. 2019 Aug 1. doi: 10.1002/jso.25656.
    PubMed     Abstract available
    
    
    July 2019
37. SON T, Sun J, Choi S, Cho M, et al
    Multi-institutional validation of the 8th AJCC TNM staging system for gastric cancer: Analysis of survival data from high-volume Eastern centers and the SEER database.
    J Surg Oncol. 2019 Jul 23. doi: 10.1002/jso.25639.
    PubMed     Abstract available
    
    
    
38. WANG JB, Zhong Q, Wang W, Desiderio J, et al
    Postoperative dynamic survival of gastric cancer patients: A multi-institutional, international analysis of 22 265 patients.
    J Surg Oncol. 2019 Jul 17. doi: 10.1002/jso.25637.
    PubMed     Abstract available
    
    
    
39. KIM SM, Lee H, Min BH, Kim JJ, et al
    A prediction model for lymph node metastasis in early-stage gastric cancer: Toward tailored lymphadenectomy.
    J Surg Oncol. 2019 Jul 13. doi: 10.1002/jso.25628.
    PubMed     Abstract available
    
    
    March 2019
40. WANG F, Hu YL, Feng Y, Guo YB, et al
    High-level expression of PRSS3 correlates with metastasis and poor prognosis in patients with gastric cancer.
    J Surg Oncol. 2019 Mar 25. doi: 10.1002/jso.25448.
    PubMed     Abstract available
    
    
    
41. VUIJK FA, Hilling DE, Mieog JSD, Vahrmeijer AL, et al
    Response to the Letter to the Editor.
    J Surg Oncol. 2019;119:399.
    PubMed    
    
    
    February 2019
42. ZHAO B, Leichman LP, Horgan S, Bouvet M, et al
    Evaluation of treatment and outcomes for Hispanic patients with gastric cancer at Commission on Cancer-accredited centers in the United States.
    J Surg Oncol. 2019 Feb 11. doi: 10.1002/jso.25408.
    PubMed     Abstract available
    
    
    
43. AGNES A, Biondi A, Cananzi FM, Rausei S, et al
    Ratio-based staging systems are better than the 7th and 8th editions of the TNM in stratifying the prognosis of gastric cancer patients: A multicenter retrospective study.
    J Surg Oncol. 2019 Feb 11. doi: 10.1002/jso.25411.
    PubMed     Abstract available
    
    
    January 2019
44. RHOME RM, Ru M, Moshier E, Mazumdar M, et al
    Stage-matched survival differences by ethnicity among gastric cancer patients of Asian ancestry treated in the United States.
    J Surg Oncol. 2019 Jan 29. doi: 10.1002/jso.25389.
    PubMed     Abstract available
    
    
    
45. DRAKE J, Schreiber KC, Lopez R, Fasaye GA, et al
    Establishing a center of excellence for hereditary diffuse gastric cancer syndrome.
    J Surg Oncol. 2019 Jan 7. doi: 10.1002/jso.25363.
    PubMed    
    
    
    December 2018
46. JIANG Z, Sun L, Yang W, Li J, et al
    Excessive expectations for carcinoembryonic antigen targeted fluorescent-guided surgery for sentinel lymph node detection in colorectal, pancreatic, and gastric cancer.
    J Surg Oncol. 2018 Dec 3. doi: 10.1002/jso.25318.
    PubMed    
    
    
    November 2018
47. ZAIDI MY, Rappaport JM, Ethun CG, Gillespie T, et al
    Identifying the barriers to gastric cancer care at safety-net hospitals: A novel comparison of a safety-net hospital to a neighboring quaternary referral academic center in the same healthcare system.
    J Surg Oncol. 2018 Nov 27. doi: 10.1002/jso.25299.
    PubMed     Abstract available
    
    
    
48. SHINKAI M, Imano M, Chiba Y, Iwama M, et al
    Phase II trial of neoadjuvant chemotherapy with intraperitoneal paclitaxel, S-1, and intravenous cisplatin and paclitaxel for stage IIIA or IIIB gastric cancer.
    J Surg Oncol. 2018 Nov 15. doi: 10.1002/jso.25295.
    PubMed     Abstract available
    
    
    October 2018
49. HE M, Jiang Z, Wang C, Hao Z, et al
    Diagnostic value of near-infrared or fluorescent indocyanine green guided sentinel lymph node mapping in gastric cancer: A systematic review and meta-analysis.
    J Surg Oncol. 2018 Oct 31. doi: 10.1002/jso.25285.
    PubMed     Abstract available
    
    
    
50. GUO X, Peng Z, Lv X, Cui J, et al
    Randomized controlled trial comparing short-term outcomes of laparoscopic and open spleen-preserving splenic hilar lymphadenectomy for advanced proximal gastric cancer: An interim report.
    J Surg Oncol. 2018 Oct 31. doi: 10.1002/jso.25262.
    PubMed     Abstract available
    
    
    
51. MARTIN AN, Silverstein A, Ssebuufu R, Lule J, et al
    Impact of delayed care on surgical management of patients with gastric cancer in a low-resource setting.
    J Surg Oncol. 2018 Oct 31. doi: 10.1002/jso.25286.
    PubMed     Abstract available
    
    
    
52. ARROYO-MARTINEZ Q, Han WH, Eom BW, Yoon HM, et al
    The distribution pattern of metastatic lymph nodes after non-curative endoscopic resection in early gastric cancer.
    J Surg Oncol. 2018 Oct 27. doi: 10.1002/jso.25279.
    PubMed     Abstract available
    
    
    
53. LI P, Huang CM, Zheng CH, Russo A, et al
    Comparison of gastric cancer survival after R0 resection in the US and China.
    J Surg Oncol. 2018 Oct 17. doi: 10.1002/jso.25220.
    PubMed     Abstract available
    
    
    September 2018
54. VUIJK FA, Hilling DE, Mieog JSD, Vahrmeijer AL, et al
    Fluorescent-guided surgery for sentinel lymph node detection in gastric cancer and carcinoembryonic antigen targeted fluorescent-guided surgery in colorectal and pancreatic cancer.
    J Surg Oncol. 2018 Sep 14. doi: 10.1002/jso.25139.
    PubMed     Abstract available
    
    
    
55. SUZUKI M, Yokobori T, Gombodorj N, Yashiro M, et al
    High stromal transforming growth factor beta-induced expression is a novel marker of progression and poor prognosis in gastric cancer.
    J Surg Oncol. 2018 Sep 9. doi: 10.1002/jso.25217.
    PubMed     Abstract available
    
    
    
56. GIULIANO K, Ejaz A, Reames BN, Choi W, et al
    Comparing the long-term outcomes among patients with stomach and small intestine gastrointestinal stromal tumors: An analysis of the National Cancer Database.
    J Surg Oncol. 2018;118:486-492.
    PubMed     Abstract available
    
    
    
57. LI Z, Li S, Bu Z, Zhang L, et al
    The effect of preoperative treatments on lymph node counts after total gastrectomy in esophagogastric adenocarcinoma.
    J Surg Oncol. 2018;118:657-663.
    PubMed     Abstract available
    
    
    July 2018
58. KUKAR M, Gabriel E, Ben-David K, Hochwald SN, et al
    Laparoscopic proximal gastrectomy for gastric neoplasms.
    J Surg Oncol. 2018;118:95-100.
    PubMed     Abstract available
    
    
    
59. COHEN NA, Strong VE, Janjigian YY
    Checkpoint blockade in esophagogastric cancer.
    J Surg Oncol. 2018;118:77-85.
    PubMed     Abstract available
    
    
    June 2018
60. IKOMA N, Hofstetter WL, Estrella JS, Das P, et al
    The ypT category does not impact overall survival in node negative gastric cancer.
    J Surg Oncol. 2018 Jun 27. doi: 10.1002/jso.25081.
    PubMed     Abstract available
    
    
    
61. YU JJ, Li JD, Yang T
    Association between neutrophil-lymphocyte ratio and prognosis after potentially curative resection for gastric cancer.
    J Surg Oncol. 2018 Jun 7. doi: 10.1002/jso.25070.
    PubMed    
    
    
    
62. THIELS CA, Ikoma N, Fournier K, Das P, et al
    Repeat staging laparoscopy for gastric cancer after preoperative therapy.
    J Surg Oncol. 2018 Jun 7. doi: 10.1002/jso.25094.
    PubMed     Abstract available
    
    
    
63. SZOR DJ, Dias AR, Pereira MA, Ramos MFKP, et al
    Reply to: "Association between neutrophil-lymphocyte ratio and prognosis after potentially curative resection for gastric cancer".
    J Surg Oncol. 2018 Jun 7. doi: 10.1002/jso.25069.
    PubMed    
    
    
    
64. LANE WO, Nussbaum DP, Sun Z, Blazer DG, et al
    Preoperative radiation therapy in the surgical management of gastric and junctional adenocarcinoma: Should lymph node retrieval guidelines be altered?
    J Surg Oncol. 2018;117:1708-1715.
    PubMed     Abstract available
    
    
    May 2018
65. KIM HS, Chon HJ, Kim H, Shin SJ, et al
    MET in gastric cancer with liver metastasis: The relationship between MET amplification and Met overexpression in primary stomach tumors and liver metastasis.
    J Surg Oncol. 2018 May 22. doi: 10.1002/jso.25097.
    PubMed     Abstract available
    
    
    
66. WEN J, Bedford M, Begum R, Mitchell H, et al
    The value of inflammation based prognostic scores in patients undergoing surgical resection for oesophageal and gastric carcinoma.
    J Surg Oncol. 2018 May 14. doi: 10.1002/jso.25057.
    PubMed     Abstract available
    
    
    March 2018
67. PEREIRA MA, Ramos MFKP, Faraj SF, Dias AR, et al
    Clinicopathological and prognostic features of Epstein-Barr virus infection, microsatellite instability, and PD-L1 expression in gastric cancer.
    J Surg Oncol. 2018 Mar 13. doi: 10.1002/jso.25022.
    PubMed     Abstract available
    
    
    
68. MARTINS MR, Santos RLD, Jatahy KDN, Matta MCD, et al
    Could OX40 agonist antibody promote activation of the anti-tumor immune response in gastric cancer?
    J Surg Oncol. 2018 Mar 12. doi: 10.1002/jso.25001.
    PubMed     Abstract available
    
    
    
69. SZOR DJ, Roncon Dias A, Pereira MA, Ramos MFKP, et al
    Neutrophil-lymphocyte ratio is associated with prognosis in patients who underwent potentially curative resection for gastric cancer.
    J Surg Oncol. 2018 Mar 6. doi: 10.1002/jso.25036.
    PubMed     Abstract available
    
    
    
70. MIZRAK KAYA D, Nogueras-Gonzalez GM, Harada K, Amlashi FG, et al
    Risk of peritoneal metastases in patients who had negative peritoneal staging and received therapy for localized gastric adenocarcinoma.
    J Surg Oncol. 2018;117:678-684.
    PubMed     Abstract available
    
    
    
71. GABRIEL E, Attwood K, Narayanan S, Brady M, et al
    Does neoadjuvant/perioperative chemotherapy improve overall survival for T2N0 gastric adenocarcinoma?
    J Surg Oncol. 2018;117:659-670.
    PubMed     Abstract available
    
    
    January 2018
72. NISHIZUKA SS, Tamura G, Nakatochi M, Fukushima N, et al
    Helicobacter pylori infection is associated with favorable outcome in advanced gastric cancer patients treated with S-1 adjuvant chemotherapy.
    J Surg Oncol. 2018 Jan 22. doi: 10.1002/jso.24977.
    PubMed     Abstract available
    
    
    December 2017
73. MURATA S, Yamamoto H, Shimizu T, Naitoh H, et al
    5-fluorouracil combined with cisplatin and mitomycin C as an optimized regimen for hyperthermic intraperitoneal chemotherapy in gastric cancer.
    J Surg Oncol. 2017 Dec 19. doi: 10.1002/jso.24906.
    PubMed     Abstract available
    
    
    
74. IKOMA N, Cloyd J, Badgwell BD, Agnes A, et al
    Clinical features and survival of gastric cancer patients with DNA mismatch repair deficiency.
    J Surg Oncol. 2017 Dec 11. doi: 10.1002/jso.24926.
    PubMed     Abstract available
    
    
    
75. LI K, Cannon JGD, Jiang SY, Sambare TD, et al
    Diagnostic staging laparoscopy in gastric cancer treatment: A cost-effectiveness analysis.
    J Surg Oncol. 2017 Dec 4. doi: 10.1002/jso.24942.
    PubMed     Abstract available
    
    
    
76. LEE JH, Tanaka E, Woo Y, Ali G, et al
    Advanced real-time multi-display educational system (ARMES): An innovative real-time audiovisual mentoring tool for complex robotic surgery.
    J Surg Oncol. 2017;116:894-897.
    PubMed     Abstract available
    
    
    November 2017
77. LIU X, Li G, Long Z, Yin J, et al
    Phase II trial of preoperative chemoradiation plus perioperative SOX chemotherapy in patients with locally advanced gastric cancer.
    J Surg Oncol. 2017 Nov 30. doi: 10.1002/jso.24917.
    PubMed     Abstract available
    
    
    
78. CHOI WJ, Moon JH, Min JS, Song YK, et al
    Real-time detection system for tumor localization during minimally invasive surgery for gastric and colon cancer removal: In vivo feasibility study in a swine model.
    J Surg Oncol. 2017 Nov 28. doi: 10.1002/jso.24922.
    PubMed     Abstract available
    
    
    August 2017
79. DUAN W, Liu K, Fu X, Shen X, et al
    Semi-end-to-end esophagojejunostomy after laparoscopy-assisted total gastrectomy better reduces stricture and leakage than the conventional end-to-side procedure: A retrospective study.
    J Surg Oncol. 2017;116:177-183.
    PubMed     Abstract available
    
    
    July 2017
80. MURATA S, Yamamoto H, Naitoh H, Yamaguchi T, et al
    Feasibility and safety of hyperthermic intraperitoneal chemotherapy using 5-fluorouracil combined with cisplatin and mitomycin C in patients undergoing gastrectomy for advanced gastric cancer.
    J Surg Oncol. 2017 Jul 25. doi: 10.1002/jso.24771.
    PubMed     Abstract available
    
    
    
81. CHEN XD, Mao CC, Zhang WT, Lin J, et al
    A quantified risk-scoring system and rating model for postsurgical gastroparesis syndrome in gastric cancer patients.
    J Surg Oncol. 2017 Jul 25. doi: 10.1002/jso.24691.
    PubMed     Abstract available
    
    
    June 2017
82. SON SY, Kong SH, Ahn HS, Park YS, et al
    The value of N staging with the positive lymph node ratio, and splenectomy, for remnant gastric cancer: A multicenter retrospective study.
    J Surg Oncol. 2017 Jun 26. doi: 10.1002/jso.24737.
    PubMed     Abstract available
    
    
    
83. SAUNDERS JH, Bowman CR, Reece-Smith AM, Pang V, et al
    The role of adjuvant platinum-based chemotherapy in esophagogastric cancer patients who received neoadjuvant chemotherapy prior to definitive surgery.
    J Surg Oncol. 2017;115:821-829.
    PubMed     Abstract available
    
    
    May 2017
84. BUSWEILER LAD, Dikken JL, Henneman D, van Berge Henegouwen MI, et al
    The influence of a composite hospital volume on outcomes for gastric cancer surgery: A Dutch population-based study.
    J Surg Oncol. 2017 May 15. doi: 10.1002/jso.24562.
    PubMed     Abstract available
    
    
    
85. LORENZON L, Cippitelli C, Avantifiori R, Uccini S, et al
    Down-regulated miRs specifically correlate with non-cardial gastric cancers and Lauren's classification system.
    J Surg Oncol. 2017 May 5. doi: 10.1002/jso.24648.
    PubMed     Abstract available
    
    
    March 2017
86. GIULIANO K, Nagarajan N, Canner J, Najafian A, et al
    Gastric and small intestine gastrointestinal stromal tumors: Do outcomes differ?
    J Surg Oncol. 2017;115:351-357.
    PubMed     Abstract available
    
    
    February 2017
87. RUSSO A, Li P, Strong VE
    Differences in the multimodal treatment of gastric cancer: East versus west.
    J Surg Oncol. 2017 Feb 9. doi: 10.1002/jso.24517.
    PubMed     Abstract available
    
    
    December 2016
88. RONA KA, Schwameis K, Zehetner J, Samakar K, et al
    Gastric cancer in the young: An advanced disease with poor prognostic features.
    J Surg Oncol. 2016 Dec 23. doi: 10.1002/jso.24533.
    PubMed     Abstract available
    
    
    November 2016
89. FEINGOLD PL, Kwong ML, Davis JL, Rudloff U, et al
    Adjuvant intraperitoneal chemotherapy for the treatment of gastric cancer at risk for peritoneal carcinomatosis: A systematic review.
    J Surg Oncol. 2016 Nov 23. doi: 10.1002/jso.24476.
    PubMed     Abstract available
    
    
    
90. POLOM K, Marrelli D, Roviello G, Pascale V, et al
    Molecular key to understand the gastric cancer biology in elderly patients-The role of microsatellite instability.
    J Surg Oncol. 2016 Nov 18. doi: 10.1002/jso.24513.
    PubMed     Abstract available
    
    
    October 2016
91. IMAMURA T, Komatsu S, Ichikawa D, Kawaguchi T, et al
    Early signet ring cell carcinoma of the stomach is related to favorable prognosis and low incidence of lymph node metastasis.
    J Surg Oncol. 2016;114:607-612.
    PubMed     Abstract available
    
    
    
92. EL-HAGE A, Ruel C, Afif W, Wissanji H, et al
    Metastatic pattern of invasive lobular carcinoma of the breast-Emphasis on gastric metastases.
    J Surg Oncol. 2016;114:543-547.
    PubMed     Abstract available
    
    
    
93. POSTLEWAIT LM, Baptiste GG, Ethun CG, Le N, et al
    A 15-year experience with gastric neuroendocrine tumors: Does type make a difference?
    J Surg Oncol. 2016;114:576-580.
    PubMed     Abstract available
    
    
    September 2016
94. GERTLER R, Richter J, Stecher L, Nitsche U, et al
    What to do after R1-resection of adenocarcinomas of the esophagogastric junction?
    J Surg Oncol. 2016;114:428-33.
    PubMed     Abstract available
    
    
    
95. RUSSELL MC
    Comparison of neoadjuvant versus a surgery first approach for gastric and esophagogastric cancer.
    J Surg Oncol. 2016;114:296-303.
    PubMed     Abstract available
    
    
    August 2016
96. BAPTISTE GG, Postlewait LM, Ethun CG, Le N, et al
    Symptomatic presentation as a predictor of recurrence in gastroenteropancreatic neuroendocrine tumors: A single institution experience over 15 years.
    J Surg Oncol. 2016;114:163-9.
    PubMed     Abstract available
    
    
    June 2016
97. HERRERA-ALMARIO G, Patane M, Sarkaria I, Strong VE, et al
    Initial report of near-infrared fluorescence imaging as an intraoperative adjunct for lymph node harvesting during robot-assisted laparoscopic gastrectomy.
    J Surg Oncol. 2016;113:768-70.
    PubMed     Abstract available
    
    
    May 2016
98. SERRANO OK, Love C, Goldman I, Huang K, et al
    The value of FDG-PET in the staging of gastric adenocarcinoma: A single institution retrospective review.
    J Surg Oncol. 2016;113:640-6.
    PubMed     Abstract available
    
    
    April 2016
99. FUENTES E, Ahmad R, Hong TS, Clark JW, et al
    The impact of neoadjuvant therapy for gastroesophageal adenocarcinoma on postoperative morbidity and mortality.
    J Surg Oncol. 2016;113:560-4.
    PubMed     Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Gastric Cancer is free of charge. This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim. Design: